PDA · BPC-157 arginate salt · GEPPPGKPADDAGLV-arginate
The same 15-amino acid peptide sequence as BPC-157, supplied as an arginate salt rather than the standard acetate salt. Emerged as the dominant alternative when BPC-157 was placed on the FDA Category 2 restricted list in 2023. Identical active sequence — different regulatory status and meaningfully better oral stability. No independent human trial data exists for PDA specifically; all evidence is extrapolated from the 180+ BPC-157 studies.
01 — Research Summary
Pentadeca Arginate has no independent human trials and no independent preclinical studies. Every study ever published on this peptide sequence used BPC-157 (acetate salt form) — not PDA. The scientific case for PDA is built entirely on the inference that the active sequence is identical, therefore the research base transfers.
That inference is scientifically reasonable. Salt forms of the same active compound routinely show equivalent biological activity — the salt is a counterion that dissociates in physiological conditions, leaving the same active peptide. The BPC-157 evidence base — 180+ studies across tissue repair, gut healing, angiogenesis, and anti-inflammatory mechanisms — is the de facto evidence base for PDA by extension.
Arginate salt form patented as "bepecin di-L-arginine salt." The arginate counterion form was patented separately from standard BPC-157 acetate, establishing the regulatory and chemical distinction that allowed compounding pharmacies to offer PDA when BPC-157 was restricted.
~1,000x better stability at stomach pH — but not peer-reviewed. Compounding pharmacy marketing materials cite HPLC-verified data showing PDA survives stomach acid (pH 3.0) approximately 1,000 times better than acetate-form BPC-157. This claim has not been published in a peer-reviewed journal as of April 2026. It originates from internal vendor documentation.
PDA did not emerge from new research — it emerged from the FDA's 2023 Category 2 restriction on BPC-157. Compounding pharmacies switched to the arginate form because it wasn't explicitly named on the restricted list. Whether that distinction is legally defensible has never been formally ruled upon by the FDA. The BPC-157 PCAC review in July 2026 may clarify this — a positive recommendation for BPC-157 would largely eliminate the regulatory rationale for choosing PDA over BPC-157.
02 — Mechanism of Action
PDA's mechanism is identical to BPC-157 — the active peptide sequence is the same, and the arginate counterion dissociates in biological conditions. The full BPC-157 mechanism applies.
BPC-157/PDA upregulates vascular endothelial growth factor, promoting formation of new blood vessels at injury sites. This is the central healing mechanism — restoring blood supply to damaged, ischaemic tissue accelerates all downstream repair processes.
The peptide modulates nitric oxide synthesis, with anti-inflammatory and vasodilatory effects that complement the angiogenic mechanism. BPC-157 at the same dose as L-arginine produces comparable NO generation in gastric tissue homogenates.
BPC-157/PDA promotes tendon fibroblast outgrowth and survival under oxidative stress, accelerating the structural repair of connective tissue. The FAK-paxillin pathway activation is the documented mechanism for tendon healing specifically.
Unlike BPC-157 acetate, the arginate salt form is meaningfully more stable at stomach pH. For gut healing applications, oral PDA reaches intestinal tissue at higher concentrations than oral BPC-157 acetate — this is PDA's one genuine, practical advantage over its predecessor.
03 — Dosing Context
Protocols mirror BPC-157 — the active compound is the same.
| Route | Dose | Frequency | Best for | PDA advantage? |
|---|---|---|---|---|
| Oral | 500 mcg | 1–2x daily | Gut healing, IBD | Yes — acid stable |
| Subcutaneous | 250–500 mcg | Daily | Systemic, musculoskeletal | No — same as BPC-157 |
| Local injection | 250 mcg | Daily | Near injury site | No — same as BPC-157 |
Typical cycle: 4–8 weeks. The clearest decision framework: for oral gut healing use, PDA is the preferable form due to acid stability. For injectable use, BPC-157 acetate and PDA are equivalent — choose based on availability, price, and sourcing quality. Once BPC-157 returns to legal compounding (pending July 2026 PCAC review), the regulatory distinction largely disappears.
04 — Community
PDA is discussed primarily in the context of BPC-157 substitution rather than as a distinct compound. The community generally understands that it's the same peptide in a different salt form, and the debate centres on whether the oral stability advantage justifies any price premium. For injectable use, most community consensus is that BPC-157 acetate and PDA are interchangeable — choose whichever is better quality and more affordable from your source.
Post-July 2026 PCAC meeting, community discussion will likely shift: if BPC-157 is cleared for legal compounding, pharmaceutical-grade BPC-157 from licensed pharmacies becomes the preferred option for supervised users, and PDA's regulatory rationale diminishes significantly.